• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Recursion Pharmaceuticals (RXRX) Is Down 5.5% After Q2 Revenue Drop And Narrower Losses - What's Changed

    Simply Wall St·08/18/2026 07:27:38
    Listen to the news
    • In the second quarter of 2026, Recursion Pharmaceuticals reported revenue of US$7.67 million, down from US$19.22 million a year earlier, while reducing its net loss to US$131.01 million compared with US$171.90 million.
    • Despite weaker top-line results, recent commentary highlighting Recursion’s AI-enabled drug discovery platform and advancing early-stage oncology trials has drawn attention to the company’s progress in industrializing drug development.
    • Now we’ll examine how Recursion’s AI-driven pipeline progress, highlighted by Morgan Stanley, interacts with its existing investment narrative and risks.

    Rare earth metals are the new gold rush. Find out which 28 stocks are leading the charge.

    Recursion Pharmaceuticals Investment Narrative Recap

    To own Recursion Pharmaceuticals, you have to believe its AI-enabled platform can convert early clinical assets into meaningful, durable drug programs despite ongoing heavy losses. The latest quarter’s lower revenue but narrower net loss does not appear to change the near term focus on clinical readouts, particularly for REC-4881 in FAP, while reinforcing the key risk that the company is still far from self-funding its ambitious R&D plans.

    The most relevant recent development is Recursion’s Q2 2026 earnings, which highlight shrinking collaboration revenue alongside continued investment in oncology trials and its AI operating system. This mix keeps the FAP program and other early studies central to the catalyst story, but also underlines the existing risk around cash burn, reliance on external funding, and the need for future access to capital as programs advance.

    Yet, while the AI story is appealing, investors should be aware that Recursion’s shrinking revenue base and ongoing cash burn could...

    Read the full narrative on Recursion Pharmaceuticals (it's free!)

    Recursion Pharmaceuticals’ narrative projects $220.9 million revenue and $35.5 million earnings by 2028.

    Uncover how Recursion Pharmaceuticals' forecasts yield a $7.00 fair value, a 125% upside to its current price.

    Exploring Other Perspectives

    RXRX 1-Year Stock Price Chart
    RXRX 1-Year Stock Price Chart

    Some of the most optimistic analysts were once modeling revenue growth near 75 percent a year and US$353.1 million by 2029, which contrasts starkly with today’s weaker top line and reminds you that even bullish views on AI driven pipelines and liquidity can shift quickly as new quarterly data arrives.

    Explore 7 other fair value estimates on Recursion Pharmaceuticals - why the stock might be worth 37% less than the current price!

    Decide For Yourself

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Interested In Other Possibilities?

    Our top stock finds are flying under the radar-for now. Get in early:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.